RT Journal Article
SR Electronic
T1 Emergence of multiple SARS-CoV-2 mutations in an immunocompromised host
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.10.20248871
DO 10.1101/2021.01.10.20248871
A1 Elham Khatamzas
A1 Alexandra Rehn
A1 Maximilian Muenchhoff
A1 Johannes Hellmuth
A1 Erik Gaitzsch
A1 Tobias Weiglein
A1 Enrico Georgi
A1 Clemens Scherer
A1 Stephanie Stecher
A1 Oliver Weigert
A1 Philipp Girl
A1 Sabine Zange
A1 Oliver T. Keppler
A1 Joachim Stemmler
A1 Michael von Bergwelt-Baildon
A1 Roman Wölfel
A1 Markus Antwerpen
YR 2021
UL http://medrxiv.org/content/early/2021/01/15/2021.01.10.20248871.abstract
AB Prolonged shedding of infectious SARS-CoV-2 has recently been reported in a number of immunosuppressed individuals with COVID-19. Here, we describe the detection of high levels of replication-competent SARS-CoV-2 in specimens taken from the respiratory tract of a B-cell depleted patient up to 154 days after initial COVID-19 diagnosis concomitant with the development of high mutation rate. In this patient, a total of 11 nonsynonymous mutations were detected in addition to the Y144 deletion in the spike protein of SARS-CoV-2.Virus evolution studies revealed a dramatic diversification in viral population coinciding with treatment with convalescent plasma and clinical respiratory deterioration. Our findings highlight the urgent need for continuous real-time surveillance of genetic changes of SARS-CoV-2 adaptation alongside immunological investigations in patients with severely compromised humoral responses who may shed infectious virus over prolonged periods of time.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partially funded by the Medical Biological Defense Research Program of the Bundeswehr Medical Service.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patients are part of the COVID-19 Registries of the LMU University Hospital Munich (CORKUM, WHO trial id DRKS00021225). Clinical and routine laboratory data was prospectively collected within the COVID-19 registries and verified and complemented by individual chart review. Patient data were pseudonymized for analysis and the study was approved by the local ethics committees of LMU University (No: 20-245). Written informed consent was obtained from each patient or authorized by proxy before any study related procedure.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll original data can be provided on request